|
1
|
Maisonneuve P and Lowenfels AB:
Epidemiology of pancreatic cancer: an update. Dig Dis. 28:645–656.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Triano LR, Chang BW and Saif MW: New
developments in the treatment of locally advanced pancreatic
cancer. In: Highlights from the 45th ASCO annual meeting; Orlando,
FL JOP. 10. pp. 366–372. 2009, PubMed/NCBI
|
|
3
|
Conroy T, Desseigne F, Ychou M, et al:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu CX, Zhang XQ, Kang LD, et al: Emodin
induces apoptosis in human prostate cancer cell LNCaP. Asian J
Androl. 10:625–634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Damodharan U, Ganesan R and Radhakrishnan
UC: Expression of MMP2 and MMP9 (gelatinases A and B) in human
colon cancer cells. Appl Biochem Biotechnol. 165:1245–1252. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo HC, Bu HQ, Luo J, et al: Emodin
potentiates the antitumor effects of gemcitabine in PANC-1
pancreatic cancer xenograft model in vivo via inhibition of
inhibitors of apoptosis. Int J Oncol. 40:1849–1857. 2012.PubMed/NCBI
|
|
7
|
Baumann S, Fas SC, Giaisi M, et al:
Wogonin preferentially kills malignant lymphocytes and suppresses
T-cell tumor growth by inducing PLCgamma1- and
Ca2+-dependent apoptosis. Blood. 111:2354–2363. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li S, Zhang B, Jiang D, Wei Y and Zhang N:
Herb network construction and co-module analysis for uncovering the
combination rule of traditional Chinese herbal formulae. BMC
Bioinformatics. 11:S62010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oh B, Hu G, Kao S, Gebski V, Walls R,
Truong L, Beale P and Clarke S: The safety and tolerability of
Chinese herbal medicine in cancer patients receiving chemotherapy:
pilot study. WebmedCentral Chinese Medicine. 2:WMC0016712011.
|
|
10
|
Yim H, Lee YH, Lee CH and Lee SK: Emodin,
an anthraquinone derivative isolated from the rhizomes of Rheum
palmatum, selectively inhibits the activity of casein kinase II as
a competitive inhibitor. Planta Med. 65:9–13. 1999. View Article : Google Scholar
|
|
11
|
Wang L, Lin L and Ye B: Electrochemical
studies of the interaction of the anticancer herbal drug emodin
with DNA. J Pharm Biomed Anal. 42:625–629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu A, Chen H, Tong H, et al: Emodin
potentiates the antitumor effects of gemcitabine in pancreatic
cancer cells via inhibition of nuclear factor-kappaB. Mol Med Rep.
4:221–227. 2011.PubMed/NCBI
|
|
13
|
Chen H, Wei W, Guo Y, et al: Enhanced
effect of gemcitabine by emodin against pancreatic cancer in
vivo via cytochrome C-regulated apoptosis. Oncol Rep.
25:1253–1261. 2011.PubMed/NCBI
|
|
14
|
Fulda S, Galluzzi L and Kroemer G:
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov.
9:447–464. 2010. View
Article : Google Scholar
|
|
15
|
Leber B, Lin J and Andrews DW: Still
embedded together binding to membranes regulates Bcl-2 protein
interactions. Oncogene. 29:5221–5230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang CL, Ma YG, Xue YX, Liu YY, Xie H and
Qiu GR: Curcumin induces small cell lung cancer NCI-H446 cell
apoptosis via the reactive oxygen species-mediated mitochondrial
pathway and not the cell death receptor pathway. DNA Cell Biol.
31:139–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ly JD, Grubb DR and Lawen A: The
mitochondrial membrane potential (deltapsi(m)) in apoptosis: an
update. Apoptosis. 8:115–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian X, Luo Y, Liu YP, et al:
Downregulation of Bcl-2 and survivin expression and release of
Smac/DIABLO involved in bufalin-induced HL-60 cell apoptosis.
Zhonghua Xue Ye Xue Za Zhi. 27:21–24. 2006.(In Chinese).
|
|
19
|
Halestrap AP: Calcium, mitochondria and
reperfusion injury: a pore way to die. Biochem Soc Trans.
34:232–237. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lopez M, Welsh K, Yuan H, et al:
Antagonists of IAP-family anti-apoptotic proteins BTI. Probe
Reports from the NIH Molecular Libraries Program. 2010
|
|
21
|
Kim MP and Gallick GE: Gemcitabine
resistance in pancreatic cancer: picking the key players. Clin
Cancer Res. 14:1284–1285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Long J, Zhang Y, Yu X, et al: Overcoming
drug resistance in pancreatic cancer. Expert Opin Ther Targets.
15:817–828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan W, Lu J, Huang M, et al: Anti-cancer
natural products isolated from Chinese medicinal herbs. Chin Med.
6:272011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei WT, Chen H, Ni ZL, et al: Antitumor
and apoptosis-promoting properties of emodin, an anthraquinone
derivative from Rheum officinale Baill, against pancreatic cancer
in mice via inhibition of Akt activation. Int J Oncol.
39:1381–1390. 2011.PubMed/NCBI
|
|
25
|
Wang QJ, Cai XB, Liu MH, Hu H, Tan XJ and
Jing XB: Apoptosis induced by emodin is associated with alterations
of intracellular acidification and reactive oxygen species in
EC-109 cells. Biochem Cell Biol. 88:767–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang W, Sun Y, Li X, et al: Emodin
potentiates the anticancer effect of cisplatin on gallbladder
cancer cells through the generation of reactive oxygen species and
the inhibition of survivin expression. Oncol Rep. 26:1143–1148.
2011.PubMed/NCBI
|
